BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29

• 

  Career Advice

  Cover Letter Do’s and Don’ts

  To help you in your job search, we’ve compiled a list of cover letter do’s and don’ts.

  November 1, 2019

   · 

  3 min read

   · 

  Katharine Hansen, PhD
• 

  Career Advice

  Cover Letters, A to Z

  Let’s take a trip through the alphabet to pick up 26 tips to optimize your cover letters.

  November 1, 2019

   · 

  5 min read

   · 

  Katharine Hansen, PhD
• 

  Drug Development

  AbbVie’s Rinvoq Likely Headed for Another Approval in a Crowded Inflammatory Market

  On the same day Novartis announced that its Cosentyx didn’t prove itself superior to AbbVie’s Humira in psoriatic arthritis, AbbVie announced that its Rinvoq met the primary endpoint in active psoriatic arthritis in its SELECT-PsA 2 Phase III trial.

  November 1, 2019

   · 

  2 min read

   · 

  Mark Terry
• 

  Business

  Amgen Invests $2.7 Billion in China’s BeiGene with Plans to Develop 20 Pipeline Drugs

  “This strategic collaboration with BeiGene will enable Amgen to serve significantly more patients by expanding our presence in the world’s most populous country,” said Robert A. Bradway, Amgen’s chairman and chief executive officer.

  November 1, 2019

   · 

  2 min read

   · 

  Mark Terry
• 

  Drug Development

  Novartis’ Cosentyx Narrowly Misses Beating Out AbbVie’s Humira in Arthritis Trial

  Novartis is careful to note that Cosentyx showed “numerically higher results versus Humira,” and that there are some statistically significant advantages of the drug over Humira.

  November 1, 2019

   · 

  3 min read

   · 

  Mark Terry
• 

  Deals

  The Roivant-Sumitomo Deal: $3 Billion, 5 Companies, $550 Million in Loans and an Option on 6 More Companies

  The agreement was formally signed yesterday.

  November 1, 2019

   · 

  3 min read

   · 

  Mark Terry
• 

  BioCapital

  Biopharma Q3: Pfizer, Merck, Amgen, Incyte and J&J

  As the third quarter of 2019 comes to an end, most biopharma companies are reporting their earnings as they head into the final lap for the year. Here’s a look at some of the bigger companies’ reports that came out this week.

  November 1, 2019

   · 

  6 min read

   · 

  Mark Terry
• 

  Genetown

  Vertex Publishes Cystic Fibrosis Results from 2 Phase III Trials

  Trikafta was approved on October 22 by the U.S. Food and Drug Administration (FDA). The drug is expected to be a useful treatment for 90% of patients with CF.

  November 1, 2019

   · 

  3 min read

   · 

  Mark Terry
• 

  Genetown

  FDA Action Alert: Lipocine, Ocular, Agile and Aquestive

  There are four PDUFA dates the U.S. Food and Drug Administration has scheduled for the rest of November to decide on drug approvals. Here’s a look.

  November 1, 2019

   · 

  3 min read

   · 

  Mark Terry
• 

  Business

  Clinical Catch-Up: October 28-Nov 1

  Even clinical trial announcements don’t slow down for Halloween. It was a typically busy week. Here’s a look.

  November 1, 2019

   · 

  9 min read

   · 

  Mark Terry